GLP-1 agonists bind to GLP-1 receptors on pancreatic beta cells, stimulating glucose-dependent insulin secretionmeaning insulin is released only when blood glucose levels are elevated
Obesity: Semaglutide is being studied as a potential treatment for obesity, particularly in individuals with comorbidities
To investigate the degradation processes of MSNs-ss-SA, TEM was used to observe their breakdown in the presence of 100 U/L amidase and 8.0 mM glutathione
For oral use only.Not for parenteral use
What's next The earliest Health Canada decisions on generic semaglutide approvals are expected in Q3 2026, per Sandoz and industry estimates, though Health Canada's review backlog may extend timelines [Source: glp1prices.ca/generic-alert]
If you have a history of thyroid cancer, pancreatitis, severe diabetic retinopathy, or are pregnant, certain GLP-1 options may be restricted